Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy

• Published in: Journal of the American Heart Association Vol. 13; no. 2; p. e030512
• Main Authors: Yu, An‐Li, Chen, Yi‐Chieh, Tsai, Cheng‐Hsuan, Wu, Yuan‐Kun Aden, Su, Mao‐Yuan, Chou, Chia‐Hung, Shun, Chia‐Tung, Hsueh, Hsueh‐Wen, Juang, Jimmy Jyh‐Ming, Lee, Ming‐Jen, Tseng, Ping‐Huei, Hsu, Chia‐Hua, Hsieh, Sung‐Tsang, Ko, Chi‐Lun, Cheng, Mei‐Fang, Chao, Chi‐Chao, Lin, Yen‐Hung
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 16.01.2024; Wiley
• Subjects: 99mTc‐pyrophosphate; eplontersen; hereditary transthyretin amyloidosis; Original Research; single‐photon emission computed tomography/computed tomography; 99mTc‐pyrophosphate; hereditary transthyretin amyloidosis; eplontersen; single‐photon emission computed tomography/computed tomography

Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the se...